I. REPORT ON BUSINESS AND PRODUCTION RESULTS IN MAY 2022
(Unit: Billion dongs)
| Criteria |
May 2022 |
YTD 31 May 2022 |
% Annual Plan |
YTD 31 May 2021 |
Growth Rate |
| Total net revenue and other incomes |
102.8 |
524.3 |
36.2% |
508.2 |
3.2% |
| Net revenue |
96.2 |
514.5 |
|
502.2 |
2.4% |
| Profit before tax |
17.1 |
102.5 |
37.3% |
97.6 |
5.0% |
Total net revenue and other incomes of Imexpharm in May 2022 attained VND 102.8 billion, being nearly equal to the figure of May in 2021. Whereas profit before tax in May 2022 reduced by 19.7% year over year.
Accumulating until end of May in 2022, total net revenue and income of Imexpharm reached VND 524.3 billion, meeting 36.2% of the annual target set by the General Meeting of Shareholders. Total net revenue within first 5 months of 2022 was VND 514.6 billion and grew by 2.5% compared to the amount of the previous year. Imexpharm mainly distributed products manufactured by the Company and such medicines made up a significant ratio in revenue structure at 98%. Total pre-tax profit accumulated until end of May 2022 attained VND 102.5 billion, which increased by 5.0% year over year.
Revenue and profit of Imexpharm experienced slow growth due to the fact that ETC channel has not fully recovered, total sales in ETC channel within the first 5 months plummeted by 31% whilst OTC rose sharply approximately 26.1%
Imexpharm has well controlled cost of goods sold. To make it clear, total cost of goods sold in 5 months of 2022 grew by 0.8% while selling expenses went up nearly 2.7% and administrative expenses raised by 19.2% due to increases in basic salaries and petrol prices.
II. IMPSTOCK IN May 2022
Total transaction volume of IMP in May were 143,500 stocks and there is no put through transaction in May 2022. The highest closing price of IMP was VND 72,000, which was recorded on May 04 2022. The average order matching amount were 7,175 shares per day. The total transaction volume of IMP in May 2022 increased compared to the previous month, however, the transaction amount was much lower than the figure of the same period last year. Total volume in May 2022 was only 16.4% in comparison with the number of the corresponding month of 2021.
III. REMARKABLE ACTIVITIES IN MAY 2022 AND PLANS IN JUNE 2022
After two year of disruptions due to the pandemic, in May 2022 Imexpharm held National Sales and Marketing Conference, one of the most meaningful activities for medical representatives nationwide to participate to share, learn and gain experiences in order to enhance their skills and boost sales of the Company.
In Jun, the activities to stimulate demand have been deploying in both ETC and OTC channel. In addition, controlling inventories and receivables would be functioned to tackle the problems of market uncertainties and plans to stockpile materials have been implemented in an appropriate and timely manner by the Company to keep business and production continuity and prevent fluctuations in gross margin.
On 24 Jun 2022, Imexpharm will pay cash dividend at 15% of the par value.